Assessed

• The FDA has approved Pasatru™ (garetosmab-grts) as the first and only treatment to reduce new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with Fibrodysplasia Ossificans Progressiva (FOP). • The approval follows the OPTIMA Phase 3 clinical trial, a multinational study designed to evaluate the drug's efficacy, safety, tolerability, and pharmacokinetics in patients with active FOP. • This development is significant as it provides a targeted therapeutic option for a rare disease, supported by previous Fast Track and Orphan Drug designations from the FDA, EMA, and Japan's Ministry of Health.

Local authorities deem UK arrivals to be children more than twice as often as border forces, Home Office data showsYoung asylum seekers in the UK are more than twice as likely to be assessed as adults by immigration officers than by social workers, according to home office data.Between July 2025 and March 2026, 4,320 initial age decisions made by immigration officials found just 1,363 new arrivals (32%) to be children. Continue reading...